We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Kalypsys Expands Its Systems Business Product Portfolio

Listen with
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: 1 minute

Kalypsys has announced the expansion of its Kalypsys Systems product offering to meet customer interest in drug discovery tools.

The Company is introducing smaller configurations of the Kalypsys Integrated Screening System tailored to meet the needs of a wider range of HTS users.

Specifically, the compound profiling capabilities and an automated protein production and purification system are designed to provide improved productivity and increased flexibility for drug discovery efforts.

“We are seeing significant interest in HTS driven by academic institutions and biotechnology companies seeking the performance capabilities usually reserved for large pharmaceutical companies,” commented Rodney Turner, Executive Director, World Wide Systems Sales.

“These latest additions to our product offerings reflect Kalypsys' continuing commitment to innovation in drug discovery technology.”

Kalypsys developed the smaller version of its Integrated HTS System with various configurations to address the needs of users who seek broad assay capability across a wide range of cellular and biochemical assays coupled with on-board compound storage capability for several hundred thousand compounds.

This entry level HTS system is particularly relevant to first-time customers and will appeal to established screening operations seeking flexibility and capability in a variety of assay formats.

“Our focus on quality and customer service combined with broad scientific expertise is an important strategic advantage for our systems business,” commented Court R. Turner, Vice President, Strategic Alliances of Kalypsys.

“As Kalypsys' internal drug discovery efforts reach new milestones with lead programs planned to enter the clinic in late 2005 and early 2006, it is exciting that the Kalypsys systems business is also making great strides in its development.”

One configuration of the Kalypsys System provides unmatched capabilities for the profiling of large and small compound libraries.

This focused functionality addresses a key bottleneck in the drug discovery process or it can be used for chemical genomics applications.

Detailed chemical mapping of compound libraries ranging from thousands to several million in cell-based or biochemical assays is seamless and fully integrated in the 1536 well format.

In addition, the automated Kalypsys Protein Production and Purification System is a response to increased customer interest in biological therapeutics, especially when working in tandem with a Kalypsys integrated Screening System.

This "turnkey" solution enables the production and purification of 96 different proteins from bacterial culture in a single day with minimal human intervention. All of these products are available immediately from Kalypsys.

To date, Kalypsys has announced technology transfer partnerships of their Kalypsys Screening Systems with Merck & Co., Inc, the National Institutes of Health, Los Alamos National Laboratories and most recently The Scripps Research Institute Florida.